Can Hydroxyzine Help with Racing Thoughts at Night?
Hydroxyzine is not recommended for treating insomnia or difficulty initiating sleep due to racing thoughts, because guideline societies explicitly advise against antihistamines for this indication, citing lack of efficacy data, problematic anticholinergic side effects, and rapid tolerance development within 3–4 days. 1
Why Hydroxyzine Is Not Appropriate
The American Academy of Sleep Medicine explicitly recommends against over-the-counter antihistamines (including hydroxyzine) for insomnia treatment because they lack robust efficacy evidence, cause strong anticholinergic effects (confusion, urinary retention, falls, daytime sedation, delirium—especially in older adults), and tolerance develops after only 3–4 days of continuous use. 1
Hydroxyzine is classified as a QT-interval-prolonging medication in both pediatric and adult populations, creating cardiac safety concerns when combined with other medications or in patients with underlying cardiac risk factors. 2
A 2023 systematic review of hydroxyzine for insomnia in adults found only mixed efficacy across sleep-onset, sleep-maintenance, and sleep-quality measures, with the most common adverse effect being dry mouth; importantly, 4 of the 5 included studies did not even report safety outcomes, highlighting the limited evidence base. 3
The review concluded that hydroxyzine could be considered only as a short-term option when previous therapies have failed, are not tolerated, or are contraindicated—not as a first-line agent for racing thoughts at bedtime. 3
What Should Be Done Instead
First-Line: Cognitive Behavioral Therapy for Insomnia (CBT-I)
The American Academy of Sleep Medicine and the American College of Physicians issue a strong recommendation that all adults with chronic insomnia—including those with racing thoughts—receive CBT-I as the initial treatment before any medication. 1
CBT-I provides superior long-term efficacy compared with pharmacotherapy, with sustained benefits after treatment discontinuation, whereas medication effects cease when stopped. 1
Core components include:
- Stimulus control – use the bed only for sleep; leave the bed if unable to fall asleep within ~20 minutes and return only when drowsy. 1
- Sleep restriction – limit time in bed to approximate actual sleep time plus 30 minutes (minimum 5 hours), adjusting weekly based on sleep efficiency. 1
- Cognitive restructuring – systematically challenge maladaptive beliefs such as "I can't sleep without medication" or catastrophic thinking about the consequences of poor sleep. 1
- Relaxation techniques – progressive muscle relaxation, guided imagery, or controlled breathing to lower physiological arousal. 1
CBT-I can be delivered via individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books—all formats show comparable effectiveness. 1
If Pharmacotherapy Is Needed After CBT-I Initiation
For Sleep-Onset Insomnia (Racing Thoughts at Bedtime)
Ramelteon 8 mg taken 30 minutes before bedtime is the preferred first-line agent because it has no abuse potential, is not a DEA-scheduled medication, does not cause withdrawal symptoms, and is particularly appropriate for patients with a history of substance use or anxiety. 1, 4
Zaleplon 10 mg (5 mg if age ≥65 years) has an ultrashort half-life (~1 hour), provides rapid sleep initiation with minimal next-day sedation, and can be taken at bedtime or even in the middle of the night when ≥4 hours remain before awakening. 1
Zolpidem 10 mg (5 mg if age ≥65 years) shortens sleep-onset latency by ~25 minutes and adds ~29 minutes to total sleep time; it should be taken within 30 minutes of bedtime with at least 7 hours remaining before planned awakening. 1
For Combined Sleep-Onset and Maintenance Problems
- Eszopiclone 2 mg (1 mg if age ≥65 years) improves both sleep onset and maintenance, increasing total sleep time by 28–57 minutes and providing moderate-to-large gains in perceived sleep quality. 1
If Comorbid Anxiety or Depression Is Present
Sedating antidepressants such as low-dose mirtazapine (7.5–30 mg) or low-dose doxepin (3–6 mg) may be considered as third-line options when first-line hypnotics have failed and the patient has comorbid depression or anxiety that would benefit from antidepressant therapy. 1
Mirtazapine at lower doses (7.5 mg) is more sedating than higher doses due to stronger histamine H₁-receptor antagonism, and it exhibits very weak anticholinergic activity and minimal cytochrome P450 inhibition, making it safe to combine with other medications. 1
Common Pitfalls to Avoid
Do not prescribe hydroxyzine as a first-line agent for insomnia; this contravenes explicit guideline recommendations and exposes patients to anticholinergic burden, QT prolongation risk, and rapid tolerance without proven benefit. 2, 1
Do not initiate any pharmacotherapy without first implementing CBT-I, because behavioral therapy provides more durable benefits than medication alone and is mandated as first-line treatment by guideline societies. 1
Do not use over-the-counter antihistamines (diphenhydramine, doxylamine, or hydroxyzine) for chronic insomnia; they lack efficacy, cause daytime sedation and confusion, and develop tolerance within days. 1
Do not combine multiple sedating agents (e.g., adding a benzodiazepine to hydroxyzine), as this markedly increases the risk of respiratory depression, cognitive impairment, falls, and complex sleep behaviors. 1
Monitoring and Reassessment
Reassess sleep parameters after 1–2 weeks of any pharmacologic intervention to evaluate sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning, and adverse effects such as morning sedation or cognitive impairment. 1
If the first-line agent fails after 2 weeks, switch to an alternative first-line agent (e.g., ramelteon ↔ zaleplon ↔ zolpidem) rather than adding a second hypnotic or increasing the dose beyond recommended limits. 1
Use the lowest effective dose for the shortest duration possible; FDA labeling indicates hypnotics are intended for ≤4 weeks of treatment for acute insomnia, and evidence beyond this period is limited. 1